Oren Livnat, an analyst from H.C. Wainwright, reiterated the Buy rating on Zevra Therapeutics (ZVRA – Research Report). The associated price target is $20.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Oren Livnat has given his Buy rating due to a combination of factors surrounding Zevra Therapeutics’ recent performance and future potential. The company reported impressive initial sales of MIPLYFFA for Niemann-Pick type C, exceeding expectations significantly. The rapid enrollment of patients, particularly from the Expanded Access Program, highlights strong demand and effective execution by the company.
Furthermore, Zevra’s financial position is robust, with substantial cash reserves bolstered by a recent PRV sale. The company’s plans to expand into the European market and potential future developments in treatments for other conditions also contribute to the positive outlook. Despite some conservative adjustments to patient growth estimates, the overall potential for peak sales remains strong, supporting the Buy rating.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $18.00 price target.